Nephroprotective effects of empagliflosin and vildagliptin
Abstract
This article presents the results of a prospective study of the cardioprotective potential of two groups of hypoglycemic drugs: sodium-glucose cotransporter 2 inhibitors (empagliflozin) and dipeptidyl peptidase 4 (vildaglpitin). 90 patients with type 2 diabetes were randomized using a random number generator into 3 groups, depending on the antihyperglycemic therapy prescribed for the next 6 months: the group that continued to receive gliclazide and metformin, the group in addition to gliclazide and metformin received vildagliptin at a dose of 100 mg/day, the group in addition to gliclazide and metformin received empaglilflozin at a dose of 25 mg/day. The addition of vildagliptin to gliclazide and metformin therapy improved glycemic control and was associated with an increase in renal filtration function calculated using cystatin C, with a simultaneous decrease in podocin excretion. The addition of empagliflozin led to an increase in the filtration function of the kidneys, calculated according to cystatin C, a decrease in the excretion of markers of tubular damage of IMT-1.
About the Authors
V. N. Vasilkova
УО «Гомельский государственный медицинский университет»
Russian Federation
Russian Federation
I. Yu. Pchelin
Санкт-Петербургский государственный университет
Russian Federation
Russian Federation
Ya. A. Borovets
УО «Гомельский государственный медицинский университет»
Russian Federation
Russian Federation
Ya. L. Navmenova
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
T. V. Mokhort
УО «Белорусский государственный медицинский университет»
Russian Federation
Russian Federation
References
1. Влияние эмпаглифлозина на состояние почек у нормогликемических крыс с сердечной недостаточностью / А.Н. Куликов [и др.] // Нефрология. - 2017. - Том 21(2). - С. 83-92.
2. Байрашева В.К. Нефропротективные свойства ингибитора ДПП-4 в условиях экспериментальной диабетической нефропатии / В.К. Байрашева [и др.] // Современные проблемы науки и образования. - 2015. - Т. 3. - С. 247(8).
3. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors / E.E. Mulvihill [et al.] // Endocr. Rev. - 2014. - Vol. 35(6). - P. 992-1019.
4. Шестакова, М.В. Выбор безопасной сахароснижающей терапии при поражении почек у больных сахарным диабетом / М.В. Шестакова // Consilium medicum. - 2016. - T. 11, No 12. - C. 12-17.
5. Effect of glycemic control on chylomicron metabolism and correlation between postprandial metabolism of plasma glucose and chylomicron in patients with type 2 diabetes treated with basal-bolus insulin therapy with or without vildagliptin / F. Okajima [et al.] // J Atheroscler Thromb. - 2017. - Vol. 24, No 2. - P. 157-168.
6. Evans M. Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus / M. Evans [et al.] // Vasc. Health Risk Manag. - 2016. - Vol. 12. - P. 337- 340.
7. Каюков, И.Г. Цистатин С в современной медицине / И.Г. Каюков, А.В. Смирнов, В.Л. Эмануэль // Нефрология. - 2012. - Т. 16, №1. - С. 22-39.
8. Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad /j.J. Carrero [et al.] // Semin Dial. - 2009. - No 22. - Р. 381-386.
9. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis /j.H. Wu [et al.] // Lancet Diabetes Endocrinol. - 2016. - Vol. 4(5). - P. 411-419. doi: 10.1016/S2213-8587 (16)00052-8
10. Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes - Mechanisms, Management, and Clinical Considerations/ C. Low Wang [et al.] // Circulation. - 2016. - Vol. 133(24). - P. 2459-2502.
11. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus / Y. Lytvyn [et al.] // Am. J. Physiol. Renal Physiol. - 2015. - Vol. 308(2). - P. 77-83.
12. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy / M. Skrtic [et al.] // Curr. Opin. Nephrol. Hypertens. - 2015 - Vol. 24(1). - P. 96-103.
Review
For citations:
Vasilkova V.N., Pchelin I.Yu., Borovets Ya.A., Navmenova Ya.L., Mokhort T.V. Nephroprotective effects of empagliflosin and vildagliptin. Medical and Biological Problems of Life Activity. 2022;(1):53-61. (In Russ.)
Views: 121
Email this article 